Anti-oxidized macrophage migration inhibitory factor (oxMIF) antibody imalumab (BAX69) in advanced solid tumors: Final results of first-in-human phase 1 study

D. Mahalingam; M. R. Patel; J. C. Sachdev; L. L. Hart; N. Halama; R. K. Ramanathan; J. Sarantopoulos; X. Liu; S. Yazji; D. Jäger; M. Yoon; G. Manzur; D. Adib; R. Kerschbaumer; A. Tsimberidou

doi:10.1093/annonc/mdw368.08

Anti-oxidized macrophage migration inhibitory factor (oxMIF) antibody imalumab (BAX69) in advanced solid tumors: Final results of first-in-human phase 1 study

D. Mahalingam, M. R. Patel, J. C. Sachdev, L. L. Hart, N. Halama, R. K. Ramanathan, J. Sarantopoulos, X. Liu, S. Yazji, D. Jäger, M. Yoon, G. Manzur, D. Adib, R. Kerschbaumer, A. Tsimberidou

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Pages (from-to)	vi116
Journal	Annals of Oncology
Volume	27
DOIs	https://doi.org/10.1093/annonc/mdw368.08
State	Published - Oct 1 2016
Externally published	Yes

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1093/annonc/mdw368.08

Cite this

Mahalingam, D., Patel, M. R., Sachdev, J. C., Hart, L. L., Halama, N., Ramanathan, R. K., Sarantopoulos, J., Liu, X., Yazji, S., Jäger, D., Yoon, M., Manzur, G., Adib, D., Kerschbaumer, R., & Tsimberidou, A. (2016). Anti-oxidized macrophage migration inhibitory factor (oxMIF) antibody imalumab (BAX69) in advanced solid tumors: Final results of first-in-human phase 1 study. Annals of Oncology, 27, vi116. https://doi.org/10.1093/annonc/mdw368.08

Anti-oxidized macrophage migration inhibitory factor (oxMIF) antibody imalumab (BAX69) in advanced solid tumors : Final results of first-in-human phase 1 study. / Mahalingam, D.; Patel, M. R.; Sachdev, J. C.; Hart, L. L.; Halama, N.; Ramanathan, R. K.; Sarantopoulos, J.; Liu, X.; Yazji, S.; Jäger, D.; Yoon, M.; Manzur, G.; Adib, D.; Kerschbaumer, R.; Tsimberidou, A.

In: Annals of Oncology, Vol. 27, 01.10.2016, p. vi116.

Research output: Contribution to journal › Article › peer-review

Mahalingam, D, Patel, MR, Sachdev, JC, Hart, LL, Halama, N, Ramanathan, RK, Sarantopoulos, J, Liu, X, Yazji, S, Jäger, D, Yoon, M, Manzur, G, Adib, D, Kerschbaumer, R & Tsimberidou, A 2016, 'Anti-oxidized macrophage migration inhibitory factor (oxMIF) antibody imalumab (BAX69) in advanced solid tumors: Final results of first-in-human phase 1 study', Annals of Oncology, vol. 27, pp. vi116. https://doi.org/10.1093/annonc/mdw368.08

Mahalingam, D. ; Patel, M. R. ; Sachdev, J. C. ; Hart, L. L. ; Halama, N. ; Ramanathan, R. K. ; Sarantopoulos, J. ; Liu, X. ; Yazji, S. ; Jäger, D. ; Yoon, M. ; Manzur, G. ; Adib, D. ; Kerschbaumer, R. ; Tsimberidou, A. / Anti-oxidized macrophage migration inhibitory factor (oxMIF) antibody imalumab (BAX69) in advanced solid tumors : Final results of first-in-human phase 1 study. In: Annals of Oncology. 2016 ; Vol. 27. pp. vi116.

@article{b04e945d8eb54241a856e4732626f777,

title = "Anti-oxidized macrophage migration inhibitory factor (oxMIF) antibody imalumab (BAX69) in advanced solid tumors: Final results of first-in-human phase 1 study",

author = "D. Mahalingam and Patel, {M. R.} and Sachdev, {J. C.} and Hart, {L. L.} and N. Halama and Ramanathan, {R. K.} and J. Sarantopoulos and X. Liu and S. Yazji and D. J{\"a}ger and M. Yoon and G. Manzur and D. Adib and R. Kerschbaumer and A. Tsimberidou",

year = "2016",

month = oct,

day = "1",

doi = "10.1093/annonc/mdw368.08",

language = "English (US)",

volume = "27",

pages = "vi116",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

}

TY - JOUR

T1 - Anti-oxidized macrophage migration inhibitory factor (oxMIF) antibody imalumab (BAX69) in advanced solid tumors

T2 - Final results of first-in-human phase 1 study

AU - Mahalingam, D.

AU - Patel, M. R.

AU - Sachdev, J. C.

AU - Hart, L. L.

AU - Halama, N.

AU - Ramanathan, R. K.

AU - Sarantopoulos, J.

AU - Liu, X.

AU - Yazji, S.

AU - Jäger, D.

AU - Yoon, M.

AU - Manzur, G.

AU - Adib, D.

AU - Kerschbaumer, R.

AU - Tsimberidou, A.

PY - 2016/10/1

Y1 - 2016/10/1

UR - http://www.scopus.com/inward/record.url?scp=85081680646&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85081680646&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdw368.08

DO - 10.1093/annonc/mdw368.08

M3 - Article

VL - 27

SP - vi116

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

ER -